Viral Infections
RSSArticles
-
Nirmatrelvir-Ritonavir in High-Risk Vaccinated and Low-Risk Unvaccinated Participants: The EPIC-SR Trial
In this Phase II-III randomized controlled clinical trial (EPIC-SR), nirmatrelvir-ritonavir was not associated with a significant difference in time to alleviation of symptoms nor COVID-19-related hospitalization or death from any cause as compared with placebo in unvaccinated individuals without risk factors for severe disease or in vaccinated individuals with a least one risk factor for severe disease.
-
Predicting Outcomes of Congenital Cytomegalovirus Infection
Congenital cytomegalovirus infection can cause hearing loss and neurologic deficits, but most affected newborns escape without sequelae. New data suggest a good prognosis if the mother’s infection was after the first trimester and if the newborn has normal hearing, a normal platelet count, and a normal head ultrasound exam.
-
Vaccine Effectiveness Against Long COVID in Children and Adolescents
Findings consistent with long COVID occur in 4.5% of infected children. COVID vaccination reduces the risk of long COVID by 50% in adolescents and by 24% in children aged 5 to 11 years.
-
Molnupiravir vs. Nirmatrelvir-Ritonavir for Early Symptomatic COVID-19
A randomized, controlled, multicenter Phase II clinical trial compared molnupiravir, ritonavir-boosted nirmatrelvir, or no drug for low-risk adult patients ages 18-50 years with symptomatic COVID-19. Viral clearance was 84% faster with ritonavir-boosted nirmatrelvir and 37% faster with molnupiravir compared to no treatment.
-
Major Cardiovascular Event Risk Reduction with Pitavastatin in Patients Living with HIV
Among participants living with HIV who are at low-to-moderate risk for cardiovascular disease, those who received pitavastatin were 35% less likely to experience a major adverse cardiovascular event over a follow-up of approximately five years vs. those who received placebo.
-
CDC Recommends RSV Vaccine for Patients in Third Trimester
The agency says this solution should be administered to patients during weeks 32 through 36 of pregnancy to protect babies against the dangerous virus, both before and shortly after birth.
-
COVID-19 Vaccine, 2023-2024 Formula (Comirnaty, Spikevax)
The newest vaccines target XBB.1.5, which is no longer the dominant circulating variant, but they offer protection against XBB.1.16 and more distant variants (e.g., EG.5.1, FL.1.1.1, and BA.2.86).
-
Comparing Sequelae After Hospitalization with COVID-19, Influenza, or Sepsis
The incidence of most selected new-onset medical conditions did not significantly differ among those who had been hospitalized with COVID-19, influenza, or sepsis.
-
Nirsevimab-alip Injection (Beyfortus)
Nirsevimab can be prescribed to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season.
-
U.S. Long COVID Strategy Takes Flight
HHS opens Office of Long COVID Research and Practice, NIH begins enrollment for key clinical trials.